-
1
-
-
67549114121
-
-
Kurian GT, Harahan JP. A historical guide to the U.S. government. New York: Oxford University Press, 1998
-
Kurian GT, Harahan JP. A historical guide to the U.S. government. New York: Oxford University Press, 1998
-
-
-
-
2
-
-
0029644362
-
Elixirs, diluents, and the passage of the 1938 federal food, drug and cosmetic act
-
Wax PM. Elixirs, diluents, and the passage of the 1938 federal food, drug and cosmetic act. Ann Intern Med 1995;122:456-61
-
(1995)
Ann Intern Med
, vol.122
, pp. 456-461
-
-
Wax, P.M.1
-
3
-
-
36549038142
-
Bolstering the FDA's drug-safety authority
-
Schultz WB. Bolstering the FDA's drug-safety authority. N Engl J Med 2007;357:2217-9
-
(2007)
N Engl J Med
, vol.357
, pp. 2217-2219
-
-
Schultz, W.B.1
-
5
-
-
67549103511
-
-
National Biosystems I. Focus Group Report: physician's perceptions of prescription drug labeling information. Focus Group. Plymouth, MN: National Biosystems, Incorporated, 1992. Report No. Contract #223-91-3501
-
National Biosystems I. Focus Group Report: physician's perceptions of prescription drug labeling information. Focus Group. Plymouth, MN: National Biosystems, Incorporated, 1992. Report No. Contract #223-91-3501
-
-
-
-
6
-
-
21744433546
-
From the FDA: What's in a label? A guide for the anesthesia practitioner
-
Chang NS, Simone AF, Schultheis LW. From the FDA: what's in a label? A guide for the anesthesia practitioner. Anesthesiology 2005;103:179-85
-
(2005)
Anesthesiology
, vol.103
, pp. 179-185
-
-
Chang, N.S.1
Simone, A.F.2
Schultheis, L.W.3
-
7
-
-
0023067716
-
-
LittleJohn JK. Package insert: view of a rural town practitioner. Drug Inf J 1987;21:63-5
-
LittleJohn JK. Package insert: view of a rural town practitioner. Drug Inf J 1987;21:63-5
-
-
-
-
8
-
-
24344465285
-
FDA standard: Good enough for government work?
-
Avorn J. FDA standard: good enough for government work? N Engl J Med 2005;353:969-72
-
(2005)
N Engl J Med
, vol.353
, pp. 969-972
-
-
Avorn, J.1
-
10
-
-
67549114120
-
Guidelines for preparing core clinical-safety information on drugs
-
CIOMS Working Group III, Geneva, Switzerland: Council for International Organizations of Medical Sciences
-
CIOMS Working Group III. Guidelines for preparing core clinical-safety information on drugs. Guidelines. Geneva, Switzerland: Council for International Organizations of Medical Sciences, 1995
-
(1995)
Guidelines
-
-
-
11
-
-
84868981645
-
-
Requirements on content and format of labeling for human prescription drug and biological products. 21 CFR § 201, 314, and 601
-
Requirements on content and format of labeling for human prescription drug and biological products. 21 CFR § 201, 314, and 601
-
-
-
-
12
-
-
33744961171
-
Highlights and a hidden hazard-the FDA's new labeling regulations
-
Avorn J, Shrank W. Highlights and a hidden hazard-the FDA's new labeling regulations. N Engl J Med 2006;354:2409-11
-
(2006)
N Engl J Med
, vol.354
, pp. 2409-2411
-
-
Avorn, J.1
Shrank, W.2
-
13
-
-
33750338501
-
Committee on the assessment of the US drug safety system
-
Institute of Medicine U.S, Baciu A, Stratton KR, Burke SP, eds. Washington, DC: National Academies Press
-
Institute of Medicine (U.S.). Committee on the assessment of the US drug safety system. The future of drug safety: promoting and protecting the health of the public. Baciu A, Stratton KR, Burke SP, eds. Washington, DC: National Academies Press, 2007
-
(2007)
The future of drug safety: Promoting and protecting the health of the public
-
-
-
15
-
-
33846413998
-
The role of litigation in defining drug risks
-
Kesselheim AS, Avorn J. The role of litigation in defining drug risks. JAMA 2007;297:308-11
-
(2007)
JAMA
, vol.297
, pp. 308-311
-
-
Kesselheim, A.S.1
Avorn, J.2
-
16
-
-
0031709689
-
Black box warnings in prescription drug labeling: Results of a survey of 206 drugs
-
Beach JE, Faich GA, Bormel FG, Sasinowski FJ. Black box warnings in prescription drug labeling: results of a survey of 206 drugs. Food Drug Law J 1998;53:403-11
-
(1998)
Food Drug Law J
, vol.53
, pp. 403-411
-
-
Beach, J.E.1
Faich, G.A.2
Bormel, F.G.3
Sasinowski, F.J.4
-
17
-
-
0036972176
-
FDA use of the black box warning: Time for reevaluation as a safety tool
-
Liang BA. FDA use of the black box warning: time for reevaluation as a safety tool. J Clin Anesth 2002;14:561-3
-
(2002)
J Clin Anesth
, vol.14
, pp. 561-563
-
-
Liang, B.A.1
-
18
-
-
19744377392
-
Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron
-
Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain E, Marty J. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology 2005;102:1094-100
-
(2005)
Anesthesiology
, vol.102
, pp. 1094-1100
-
-
Charbit, B.1
Albaladejo, P.2
Funck-Brentano, C.3
Legrand, M.4
Samain, E.5
Marty, J.6
-
19
-
-
34748817466
-
Droperidol-induced proarrhythmia: The beginning of an answer?
-
Charbit B, Funck-Brentano C. Droperidol-induced proarrhythmia: the beginning of an answer? Anesthesiology 2007; 107:524-6
-
(2007)
Anesthesiology
, vol.107
, pp. 524-526
-
-
Charbit, B.1
Funck-Brentano, C.2
-
20
-
-
34748849489
-
Does low-dose droperidol administration increase the risk of druginduced QT prolongation and torsade de pointes in the general surgical population?
-
Nuttall GA, Eckerman KM, Jacob KA, Pawlaski EM, Wigersma SK, Marienau ME, Oliver WC, Narr BJ, Ackerman MJ. Does low-dose droperidol administration increase the risk of druginduced QT prolongation and torsade de pointes in the general surgical population? Anesthesiology 2007;107:531-6
-
(2007)
Anesthesiology
, vol.107
, pp. 531-536
-
-
Nuttall, G.A.1
Eckerman, K.M.2
Jacob, K.A.3
Pawlaski, E.M.4
Wigersma, S.K.5
Marienau, M.E.6
Oliver, W.C.7
Narr, B.J.8
Ackerman, M.J.9
-
21
-
-
19744369642
-
Effect of low-dose droperidol on the QT interval during and after general anesthesia: A placebo-controlled study
-
White PF, Song D, Abrao J, Klein KW, Navarette B. Effect of low-dose droperidol on the QT interval during and after general anesthesia: a placebo-controlled study. Anesthesiology 2005; 102:1101-5
-
(2005)
Anesthesiology
, vol.102
, pp. 1101-1105
-
-
White, P.F.1
Song, D.2
Abrao, J.3
Klein, K.W.4
Navarette, B.5
-
22
-
-
33745782075
-
FDA drug prescribing warnings: Is the black box half empty or half full?
-
Wagner AK, Chan KA, Dashevsky I, Raebel MA, Andrade SE, Lafata JE, Davis RL, Gurwitz JH, Soumerai SB, Platt R. FDA drug prescribing warnings: is the black box half empty or half full? Pharmacoepidemiol Drug Saf 2006;15:369-86
-
(2006)
Pharmacoepidemiol Drug Saf
, vol.15
, pp. 369-386
-
-
Wagner, A.K.1
Chan, K.A.2
Dashevsky, I.3
Raebel, M.A.4
Andrade, S.E.5
Lafata, J.E.6
Davis, R.L.7
Gurwitz, J.H.8
Soumerai, S.B.9
Platt, R.10
-
23
-
-
0036395265
-
Risk management strategies in the Physicians' Desk Reference product labels for pregnancy category X drugs
-
Uhl K, Kennedy DL, Kweder SL. Risk management strategies in the Physicians' Desk Reference product labels for pregnancy category X drugs. Drug Saf 2002;25:885-92
-
(2002)
Drug Saf
, vol.25
, pp. 885-892
-
-
Uhl, K.1
Kennedy, D.L.2
Kweder, S.L.3
-
25
-
-
0027642031
-
Perceived readability of warning labels with varied font sizes and styles
-
Silver NC, Braun CC. Perceived readability of warning labels with varied font sizes and styles. Saf Sci 1993;16:615-25
-
(1993)
Saf Sci
, vol.16
, pp. 615-625
-
-
Silver, N.C.1
Braun, C.C.2
-
26
-
-
84868981647
-
-
FDA proposes rules for dissemination information on off-label uses. Available at:, Accessed March 5, 2008
-
FDA proposes rules for dissemination information on off-label uses. Available at: www.fda.gov/bbs/topics/NEWS/NEW00643. html. Accessed March 5, 2008
-
-
-
-
27
-
-
0042512222
-
Off-label or out of bounds? Prescriber and marketer liability for unapproved uses of FDA-approved drugs
-
O'Reilly J, Dalal A. Off-label or out of bounds? Prescriber and marketer liability for unapproved uses of FDA-approved drugs. Ann Health Law 2003;12:295-324
-
(2003)
Ann Health Law
, vol.12
, pp. 295-324
-
-
O'Reilly, J.1
Dalal, A.2
-
28
-
-
67549126255
-
-
Sorrel AL. Off-label probes are looking into physicians' role. Amednews Com [serial online], 2006. Available at: http://www.ama-assn.org/amednews/2006/ 08/21/gvsb0821.htm. Accessed March 5, 2008
-
Sorrel AL. Off-label probes are looking into physicians' role. Amednews Com [serial online], 2006. Available at: http://www.ama-assn.org/amednews/2006/ 08/21/gvsb0821.htm. Accessed March 5, 2008
-
-
-
-
29
-
-
84868989266
-
-
is under assault. Available at:, Accessed March 5, 2008
-
The FDA's reputation with the general public is under assault. Available at: http://harrisinteractive.com/news/allnewsbydate. asp?NewsID-1060. Accessed March 5, 2008
-
The FDA's reputation with the general public
-
-
-
30
-
-
4344644259
-
Scandals have eroded US public's confidence in drug industry
-
Lenzer J. Scandals have eroded US public's confidence in drug industry. BMJ 2004;329:247
-
(2004)
BMJ
, vol.329
, pp. 247
-
-
Lenzer, J.1
-
31
-
-
67549111706
-
-
The future of drug safety: promoting and protecting the health of the public, FDA's response to the Institute of Medicine's 2006 report. Available at: http://www.fda.gov/oc/reports/iom013007. html. Accessed March 5, 2008
-
The future of drug safety: promoting and protecting the health of the public, FDA's response to the Institute of Medicine's 2006 report. Available at: http://www.fda.gov/oc/reports/iom013007. html. Accessed March 5, 2008
-
-
-
-
32
-
-
34247871340
-
FDA responds to Institute of Medicine drug safety recommendations-in part
-
Psaty BM, Charo RA. FDA responds to Institute of Medicine drug safety recommendations-in part. JAMA 2007;297:1917-20
-
(2007)
JAMA
, vol.297
, pp. 1917-1920
-
-
Psaty, B.M.1
Charo, R.A.2
-
33
-
-
61749098380
-
-
The Sentinel Initiative:, Rockville, MD: U.S. Department of Health and Human Services, Office of Critical Path Programs
-
The Sentinel Initiative: National strategy for monitoring medical product safety. Rockville, MD: U.S. Department of Health and Human Services, Office of Critical Path Programs, 2008
-
(2008)
National strategy for monitoring medical product safety
-
-
-
34
-
-
33646183685
-
How the US drug safety system should be changed
-
Strom BL. How the US drug safety system should be changed. JAMA 2006;295:2072-5
-
(2006)
JAMA
, vol.295
, pp. 2072-2075
-
-
Strom, B.L.1
-
35
-
-
84868976899
-
-
Available at:, Accessed March, 5, 2008
-
Imdicon. Available at: www.fda.gov/cder/regulatory/physLabel/ Imdicon.pdf. Accessed March, 5, 2008
-
Imdicon
-
-
|